[{"id":"3fbb4956-9efb-48d1-85dd-3eccb081995e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05128786","created_at":"2021-11-22T14:53:25.733Z","updated_at":"2024-07-02T16:35:50.288Z","phase":"Phase 1","brief_title":"CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas","source_id_and_acronym":"NCT05128786","lead_sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","biomarkers":" AXL","pipe":" | ","alterations":" AXL positive","tags":["AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CCT301-038"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2023-04-18"},{"id":"57590c99-52a7-47e1-b57d-87dc82ca1906","acronym":"","url":"https://clinicaltrials.gov/study/NCT03393936","created_at":"2021-01-18T16:44:54.019Z","updated_at":"2024-07-02T16:36:22.653Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma","source_id_and_acronym":"NCT03393936","lead_sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","biomarkers":" AXL • ROR2","pipe":"","alterations":" ","tags":["AXL • ROR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CCT301-038 • CCT301-59"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-10-21"}]